ClinicalTrials.gg
RecruitingNCT07476287Updated Oct 9, 2026

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

A Phase 2 interventional study of PF-08634404 and Chemotherapy in Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ) and Transformed Small Cell Lung Cancer, sponsored by Pfizer. Recruiting at 61 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 9, 2026First sites in Australia and IndiaSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Small Cell Lung Carcinoma by Pfizer — 4 open to participants now, 5 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Pfizer.

Planned enrollment
11th of 12
40 · median 227
Started
2026
the only one that year
Phase 2
4 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Small Cell Lung Carcinoma by Pfizer, this one is the 11th largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 2, and was the 12th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

4 of the 12 studies in Small Cell Lung Carcinoma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Small Cell Lung Carcinoma by Pfizer, or all of them as a file.
02

Study summary

This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working.

To join the study, participants must meet the following conditions:

  • Are aged 18 years or older
  • Diagnosed with T-SCLC and have not received treatment for this type of lung cancer (a single cycle of chemotherapy may be permitted)
  • Prior diagnosis of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors (TKIs)
  • Have healthy organs based on medical tests and are in good physical condition

After joining the study, adults will be given chemotherapy in addition to the study medicine. After this combination treatment is finished, the study medicine will be continued alone. Adults will receive the treatment through IV infusions (medicine given directly into a vein). All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit.

03

Conditions studied

  • Small Cell Lung Cancer
  • Small Cell Lung Cancer ( SCLC )
  • Transformed Small Cell Lung Cancer
  • Lung Neoplasms
  • Carcinoma, Small Cell Lung
  • Small Cell Cancer Of The Lung

Keywords

  • Transformed Small Cell Lung Cancer
  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged ≥18 years at the time of .
  • or cytologically confirmed T-SCLC. Participant must have had a prior diagnosis of NSCLC with EGFR mutation which transformed to SCLC following the treatment with TKI(s).
  • Participants have not received systemic therapy for T-SCLC.
  • Have at least one as the target lesion based on v1.1.
  • Have sufficient tumor tissue from the diagnosis of transformed SCLC available.
  • performance status of 0 or 1.
  • Have a minimum of >12 weeks.
  • Clinical laboratory values at screening within acceptable limits, as defined in the protocol, including: 1) Hematology, 2) Liver function and 3) Renal function.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Active or untreated CNS disease, including brain, brainstem, spinal cord, or meningeal . Participants with definitively treated, clinically stable may be eligible per protocol criteria. Participants with untreated asymptomatic brain metastases of longest diameter \<1 cm are permitted if all of the following criteria are met: absence of neurological symptoms, no need for , and brain metastasis has no evidence of edema or hemorrhagic features.
  • risk of hemorrhage or fistula, including tumor necrosis/cavitation, invasion or compression of major blood vessels, airways, or critical organs, or risk of tracheoesophageal or pleuroesophageal fistula
  • History of another (other than NSCLC) within 3 years prior to first dose, except for malignancies with negligible risk of metastasis or death (eg, adequately treated carcinoma in situ, nonmelanoma skin cancer)
  • Unresolved toxicity from prior anti-tumor therapy that has not recovered to Grade ≤1 per v5.0 (except alopecia or irreversible toxicities deemed stable)
  • History of allogeneic organ or hematopoietic stem cell transplantation
  • Active disease requiring systemic treatment within the past 2 years (Stable replacement therapy and selected low-risk autoimmune conditions are permitted per protocol)
  • Interstitial lung disease (ILD), pneumonitis, or significant pulmonary disease, including:

    • Prior or current non-infectious pneumonitis requiring systemic therapy
    • DLCO \<50% predicted
    • Severe asthma, , pulmonary embolism, or autoimmune lung involvement
  • Uncontrolled or clinically significant cardiovascular, cerebrovascular, metabolic, hepatic, or renal disease within 6 months prior to first dose
  • Baseline >480 msec
  • Major surgery or severe trauma within 4 weeks prior to first dose, or planned major surgery during the study
  • Clinically significant pleural effusion, pericardial effusion, or ascites requiring repeated drainage
  • History of significant bleeding disorders or recent major bleeding events
  • Clinically significant gastrointestinal conditions, including recent perforation, fistula, obstruction, or active bleeding
  • Active, uncontrolled, or symptomatic infection, including:

    • Active TB
    • Active or C
    • Uncontrolled infection
  • History of immunodeficiency
  • Severe or allergic reactions to study intervention components or monoclonal antibodies
  • Psychiatric illness or medical condition, including recent suicidal ideation or behavior, that may increase risk or interfere with study participation
  • Prior anti-angiogenic therapy or other prohibited anti-tumor or immunomodulatory therapies per protocol-specified
  • Use of prohibited concomitant medications, including high-dose systemic corticosteroids, certain anticoagulants, or within protocol-specified timeframes
  • Recent participation in another study (within 30 days or 5 half-lives, whichever is longer)
  • Pregnant or breastfeeding participants, or unwillingness to comply with requirements
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    PF-08634404

    Participants will receive PF-08634404 in combination with chemotherapy intravenously, followed by maintenance therapy with PF-08634404.

    Drug: PF-08634404 · Drug: Chemotherapy

Interventions

  • Concentrate for solution for infusion

    Also known as: SSGJ-707

  • DrugChemotherapy

    Injection for intravenous use

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (ORR) as assessed by investigator based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

    Defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) is observed as best overall response. ORR using RECIST v1.1 as assessed by investigator.

    Time frame: From start of treatment until first documented CR or PR (approximately maximum up to 1 years)

  2. Number of Participants with Adverse Events (AEs)

    Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

    Time frame: Up to 90 days after the last dose of treatment

Secondary outcomes

  1. Duration of Response (DOR) as assessed by investigator based on RECIST v1.1

    DOR is defined as the time from the first documentation of objective response (CR or PR) to the date of first documentation of disease progression (PD) or death due to any cause.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  2. Progression Free Survival (PFS) as assessed by investigator based on RECIST v1.1

    PFS is defined as the time from the date of randomization to the date of first documented disease progression, per RECIST v1.1, or death to any cause, whichever occurs first

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  3. Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death due to any cause. OS is secondary outcome measure in Phase 2 portion of the study.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  4. Number of participants with Laboratory abnormalities

    Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.

    Time frame: Up to 90 days after the last dose of treatment

  5. Pharmacokinetics: Predose and postdose Serum concentrations of PF-08634404

    Time frame: Up to 37 days after the last dose of treatment

  6. Incidence of antidrug antibody against PF-08634404

    Time frame: Up to 37 days after the last dose of treatment

07

Study locations

55 of 61 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Mar 2028, 20 months after the start.

Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's planned 20 months is below that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 17, 2026
StartActual
Jul 2, 2026
Primary completionEst.
Mar 24, 2028
CompletionEst.
Mar 24, 2031
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
43 sites added, 12 sites removed — first sites in Australia and India. 6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • Fujian Cancer Hospital · Fuzhou, ChinaNot yet recruiting→Recruiting
  • Henan Cancer Hospital · Zhengzhou, ChinaNot yet recruiting→Recruiting
  • Centre Léon Bérard · Lyon, FranceNot yet recruiting→Recruiting
  • Queen Mary Hospital · Hong Kong, Hong KongNot yet recruiting→Recruiting
  • Institut Català d'Oncologia - L'Hospitalet · L'Hospitalet de Llobregat, SpainNot yet recruiting→Recruiting
  • The first Affiliated Hospital, Zhejiang University School of Medicine · Hangzhou, ChinaNot yet recruiting→Recruiting
Show 43 added (20 United States, 4 Italy, 4 Japan, 4 Spain, 3 Australia, 2 Brazil, 2 France, 2 India, 1 China, 1 Hong Kong)
  • UC San Diego Medical Center - Encinitas · Encinitas, United States
  • UC San Diego Koman Family Outpatient Pavilion · La Jolla, United States
  • UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion) · La Jolla, United States
  • UC San Diego Moores Cancer Center · La Jolla, United States
  • UC San Diego Sulpizio Cardiovascular Center · La Jolla, United States
  • UC San Diego Medical Center - Bankers Hill · San Diego, United States
  • UC San Diego McGrath Outpatient Pavilion - Hillcrest · San Diego, United States
  • UC San Diego Medical Center- Hillcrest · San Diego, United States
  • UC San Diego Medical Center - Rancho Bernardo · San Diego, United States
  • UC San Diego Medical Center - Vista · Vista, United States
  • MSK Basking Ridge · Basking Ridge, United States
  • MSK Monmouth · Middletown, United States
  • MSK Bergen. · Montvale, United States
  • MSK Commack · Commack, United States
  • MSK Westchester · East White Plains, United States
  • Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy · Long Island City, United States
  • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). · New York, United States
  • Memorial Sloan Kettering Cancer Center · New York, United States
  • MSK Nassau · Uniondale, United States
  • Calvary Connery Centre · Elizabeth Vale, Australia
  • Hospital Beneficência Portuguesa de São Paulo · São Paulo, Brazil
  • The first Affiliated Hospital, Zhejiang University School of Medicine · Hangzhou, China
  • Assistance Publique Hôpitaux de Marseille - Hôpital Nord · Marseille, France
  • Institut Gustave Roussy · Villejuif, France
  • Prince of Wales Hospital · Hong Kong, Hong Kong
  • Caritas Hospital and Institute of Health Sciences · Kottayam, India
  • Rajiv Gandhi Cancer Institute And Research Centre · New Delhi, India
  • Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni · Bergamo, Italy
  • A.O.U. San Luigi Gonzaga · Orbassano, Italy
  • Aichi Cancer Center Hospital · Nagoya, Japan
  • …and 13 more on the registry record
Show 12 removed
  • Institut Gustave Roussy · Villejuif, France
  • A.O.U. San Luigi Gonzaga · Orbassano, Italy
  • Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni · Bergamo, Italy
  • Osaka International Cancer Institute(OICI) · Osaka, Japan
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Universitario Virgen Del Rocio · Seville, Spain
  • MSK Westchester · East White Plains, United States
  • Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni · Bergamo, Italy
  • A.O.U. San Luigi Gonzaga · Orbassano, Italy
  • Osaka International Cancer Institute(OICI) · Osaka, Japan
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Universitario Virgen Del Rocio · Seville, Spain
across 2 updates, Sep 28, 2026 – Oct 9, 2026
Primary completion
Mar 19, 2028→Mar 24, 2028
Sep 28, 2026
Study completion
Mar 19, 2031→Mar 24, 2031
Sep 28, 2026
Show all 2 updates
  1. Oct 9, 2026
    10 sites added, 6 sites removed. The first Affiliated Hospital, Zhejiang University School of Medicine is now Recruiting
    Show 10 added (2 Australia, 2 Italy, 2 Japan, 2 Spain, 1 United States, 1 Brazil)
    • MSK Westchester · Harrison, United States
    • Westmead Hospital · Westmead, Australia
    • Warringal Private Hospital · Heidelberg, Australia
    • Centro Paulista de Oncologia Clínica · São Paulo, Brazil
    • A.O.U. San Luigi Gonzaga · Orbassano, Italy
    • Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni · Bergamo, Italy
    • Okayama University Hospital · Kita, Japan
    • Osaka International Cancer Institute(OICI) · Osaka, Japan
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Universitario Virgen Del Rocio · Seville, Spain
    Show 6 removed
    • MSK Westchester · East White Plains, United States
    • Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni · Bergamo, Italy
    • A.O.U. San Luigi Gonzaga · Orbassano, Italy
    • Osaka International Cancer Institute(OICI) · Osaka, Japan
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Universitario Virgen Del Rocio · Seville, Spain
    + 1 other change: verification date
  2. Sep 28, 2026
    33 sites added, 6 sites removed — first sites in Australia and India. 5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • Fujian Cancer Hospital · Fuzhou, ChinaNot yet recruiting→Recruiting
    • Henan Cancer Hospital · Zhengzhou, ChinaNot yet recruiting→Recruiting
    • Centre Léon Bérard · Lyon, FranceNot yet recruiting→Recruiting
    • Queen Mary Hospital · Hong Kong, Hong KongNot yet recruiting→Recruiting
    • Institut Català d'Oncologia - L'Hospitalet · L'Hospitalet de Llobregat, SpainNot yet recruiting→Recruiting
    Show 33 added (19 United States, 2 France, 2 India, 2 Italy, 2 Japan, 2 Spain, 1 Australia, 1 Brazil, 1 China, 1 Hong Kong)
    • UC San Diego Medical Center - Encinitas · Encinitas, United States
    • UC San Diego Koman Family Outpatient Pavilion · La Jolla, United States
    • UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion) · La Jolla, United States
    • UC San Diego Moores Cancer Center · La Jolla, United States
    • UC San Diego Sulpizio Cardiovascular Center · La Jolla, United States
    • UC San Diego Medical Center - Bankers Hill · San Diego, United States
    • UC San Diego McGrath Outpatient Pavilion - Hillcrest · San Diego, United States
    • UC San Diego Medical Center- Hillcrest · San Diego, United States
    • UC San Diego Medical Center - Rancho Bernardo · San Diego, United States
    • UC San Diego Medical Center - Vista · Vista, United States
    • MSK Basking Ridge · Basking Ridge, United States
    • MSK Monmouth · Middletown, United States
    • MSK Bergen. · Montvale, United States
    • MSK Commack · Commack, United States
    • MSK Westchester · East White Plains, United States
    • Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy · Long Island City, United States
    • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). · New York, United States
    • Memorial Sloan Kettering Cancer Center · New York, United States
    • MSK Nassau · Uniondale, United States
    • Calvary Connery Centre · Elizabeth Vale, Australia
    • Hospital Beneficência Portuguesa de São Paulo · São Paulo, Brazil
    • The first Affiliated Hospital, Zhejiang University School of Medicine · Hangzhou, China
    • Assistance Publique Hôpitaux de Marseille - Hôpital Nord · Marseille, France
    • Institut Gustave Roussy · Villejuif, France
    • Prince of Wales Hospital · Hong Kong, Hong Kong
    • Caritas Hospital and Institute of Health Sciences · Kottayam, India
    • Rajiv Gandhi Cancer Institute And Research Centre · New Delhi, India
    • Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni · Bergamo, Italy
    • A.O.U. San Luigi Gonzaga · Orbassano, Italy
    • Aichi Cancer Center Hospital · Nagoya, Japan
    • …and 3 more on the registry record
    Show 6 removed
    • Institut Gustave Roussy · Villejuif, France
    • A.O.U. San Luigi Gonzaga · Orbassano, Italy
    • Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni · Bergamo, Italy
    • Osaka International Cancer Institute(OICI) · Osaka, Japan
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Universitario Virgen Del Rocio · Seville, Spain
    Primary completion Mar 19, 2028→Mar 24, 2028
    Study completion Mar 19, 2031→Mar 24, 2031
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07476287
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Jul 2, 2026
Primary completion
Mar 24, 2028 (estimated)
Completion
Mar 24, 2031 (estimated)
Last update
Oct 9, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404

Start the discussion